Wird geladen...
How I monitor residual disease in chronic myeloid leukemia
Molecular monitoring in chronic myeloid leukemia (CML) is a powerful tool to document treatment responses and predict relapse. Nonetheless, the proliferation of clinical trials and “guidelines” using the molecular endpoints of CML has outpaced practice norms, commercial laboratory application, and r...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
American Society of Hematology
2009
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3654782/ https://ncbi.nlm.nih.gov/pubmed/19661271 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-02-163485 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|